



RESEARCH REPORT MARCH 2019



SYNDROMIC MULTIPLEX DIAGNOSTIC MARKETS.

Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Country. With Market Analysis, Executive Guides and Customization.

2019 to 2023 - Global Version



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- i. Market Guides 19
 - iA. Situation Analysis 20
 - iB. Guide for Executives and Marketing Staff 23
 - iC. Guide for Investment Analysts and Management Consultants 25
- 1. Introduction and Market Definition..... 26
 - 1.1 What are Syndromic Multiplex Tests? 27
 - 1.2 Syndromic Testing – the quiet revolution in diagnostics 28
 - 1.2.1 Syndromic Testing – more than Panels. 29
 - 1.3 Market Definition 30
 - 1.3.1 Multiplex Market Size 30
 - 1.3.2 Panel Market Size 31
 - 1.3.2 Currency 31
 - 1.3.3 Years 31
 - 1.4 Methodology 31
 - 1.4.1 Authors 31
 - 1.4.2 Sources 32
 - 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective 32
 - 1.5.1 U.S. Medicare Expenditures for Clinical Testing 34
- 2. The Infectious Diseases – Guide to the Pathogens..... 36
 - 2.1 HIV - Human Immunodeficiency Virus (AIDS) 37
 - 2.1.1 Virology 37
 - 2.1.1.1 Classification 37
 - 2.1.1.2 Structure and genome 38

- 2.1.1.3 Tropism 40
- 2.1.1.4 Replication cycle..... 42
- 2.1.1.5 Genetic variability 48
- 2.1.2 Diagnosis 50
- 2.1.3 Testing..... 51
 - 2.1.3.1 Antibody tests 51
 - 2.1.3.2 Point of Care Tests (POCT) 54
 - 2.1.3.4 Antigen Tests 56
 - 2.1.3.5 Nucleic acid-based tests (NAT) 57
 - 2.1.3.6 Other tests used in HIV treatment 58
- 2.2 HBV – Hepatitis B..... 60
 - 2.2.1 Virology 61
 - 2.2.1.1 Genome 62
 - 2.2.1.2 Pathogenesis..... 63
 - 2.2.1.3 Hepatitis B virus replication..... 63
 - 2.2.1.4 Serotypes and genotypes..... 64
 - 2.2.2 Mechanisms..... 64
 - 2.2.3 Diagnosis 65
 - 2.2.4 Market Opportunity Analysis 66
- 2.3 HCV – Hepatitis C 68
 - 2.3.1 Taxonomy..... 69
 - 2.3.2.1 Structure..... 69
 - 2.3.2.2 Genome 70
 - 2.3.3 Molecular biology..... 71
 - 2.3.4 Replication..... 72
 - 2.3.5 Genotypes 74

- 2.3.5.1 Clinical importance 74
- 2.3.6 Market Opportunity Analysis 75
- 2.4 HPV - Human papillomavirus 77
 - 2.4.1 Virology 79
 - 2.4.1.1 E6/E7 proteins..... 79
 - 2.4.1.2 Role in cancer..... 79
 - 2.4.1.3 E2 research..... 80
 - 2.4.1.4 Latency period 81
 - 2.4.1.5 Clearance 81
 - 2.4.2 Diagnosis 82
 - 2.4.2.1 Cervical testing..... 82
 - 2.4.2.2 Oral testing..... 84
 - 2.4.2.3 Testing men 84
 - 2.4.2.4 Other testing..... 85
 - 2.4.3 Market Opportunity Analysis 86
- 2.5 Influenza 92
 - 2.5.1 Virology 93
 - 2.5.1.1 Types of virus..... 93
 - 2.5.1.2 Influenzavirus A 93
 - 2.5.1.3 Influenzavirus B..... 94
 - 2.5.1.4 Influenzavirus C 94
 - 2.5.1.5 Structure, properties, and subtype nomenclature 95
 - 2.5.1.6 Replication 96
 - 2.5.2 Testing..... 98
 - 2.5.2.1 Advantages/Disadvantages of Molecular Assays 100
 - 2.5.3 Market Opportunity Analysis 101

2.6 CTGC - Chlamydia/Gonorrhea..... 110

 2.6.1 Gonorrhea 110

 2.6.1.1 Diagnosis..... 111

 2.6.1.2 Screening..... 111

 2.6.2 Chlamydia 111

 2.6.2.1 Diagnosis..... 112

 2.6.2.2 Screening..... 113

 2.6.3 Testing..... 114

 2.6.3.1 Nucleic acid amplification tests (NAATs)..... 114

 2.6.3.2 Performance of NAAT Tests 122

 2.6.4 Market Opportunity Analysis 123

2.7 Tuberculosis 126

 2.7.1 Mycobacteria 127

 2.7.2 Diagnosis 128

 2.7.2.1 Active tuberculosis 128

 2.7.2.2 Latent tuberculosis 129

 2.7.3 Epidemiology..... 129

 2.7.4 Molecular Diagnostic Tests 131

 2.7.5 Market Opportunity Analysis 132

2.8 MRSA - Methicillin-resistant Staphylococcus aureus 134

 2.8.1 Diagnosis 134

 2.8.2 FDA Approved Molecular Tests..... 135

 2.8.3 Market Opportunity Analysis 136

2.9 VRE - Vancomycin-resistant Enterococcus 137

 2.9.1 FDA Approved MDx Tests for VRE 138

 2.9.2 Market Opportunity Analysis 139

3. Industry Overview 140

3.1 Industry Participants..... 141

 3.1.1 IVD Supplier..... 141

 3.1.2 Independent lab specialized/esoteric 142

 3.1.3 Independent lab national/regional..... 142

 3.1.4 Independent lab analytical 143

 3.1.5 Public National/regional lab 143

 3.1.6 Hospital lab 143

 3.1.7 Physician lab..... 144

 3.1.8 Audit body 144

3.2 The Clinical Laboratory Market Segments..... 146

 3.2.1 Traditional Market Segmentation 146

 3.2.2 Laboratory Focus and Segmentation..... 147

 3.2.3 Segmenting the Syndromic Testing Market 149

3.3 Industry Structure 151

 3.3.1 Hospital Testing Share..... 151

 3.3.2 Economies of Scale 151

 3.3.2.1 Hospital vs. Central Lab 152

 3.3.3 Physician Office Lab's 153

 3.3.4 Physician's and POCT..... 153

4. Market Trends 155

4.1 Factors Driving Growth 156

 4.1.1 Speed of Diagnosis 156

 4.1.2 Effect of Syndromic Testing on Costs. 157

 4.1.3 Point of Care Advantage..... 157

 4.1.4 Syndrome Testing, Accuracy and Diagnostic Risk..... 157

- 4.1.5 Single Visits 157
- 4.1.6 Improvement in Outcomes. 159
- 4.2 Factors Limiting Growth 160
 - 4.2.1 Lower Prices 160
 - 4.2.2 Infectious Disease is Declining But.... 162
 - 4.2.3 Wellness Hurts. 162
 - 4.2.4 Economic Growth improves Living Standards..... 162
- 4.3 Instrumentation and Automation 164
 - 4.3.1 Instruments Key to Market Share 164
 - 4.3.2 The Shrinking Machine. 164
 - 4.3.3 Syndrome Testing Moving to Big Instruments?..... 165
- 4.4 Diagnostic Technology Development 165
 - 4.4.1 Comparing Syndrome and Targeted Testing 166
 - 4.4.2 The Multiplex Paradigm Shift 167
 - 4.4.2 The Sepsis Testing Market – Bellwether for Syndromics..... 168
 - 4.4.3 The Single Visit and AntiMicrobial Resistance 168
 - 4.4.4 Syndromics drives POCT adoption 169
 - 4.4.5 A Big Future for PCR?..... 169
- 5. Syndromic Testing Recent Developments 171
 - Recent Developments – Importance and How to Use This Section 172
 - Importance of These Developments 172
 - How to Use This Section 172
 - Akonni Biosystems Submits Multiplex Diagnostics System to FDA 172
 - Ador Diagnostic to receive \$30M in Funding for 100-Plex PoC 173
 - SAW Diagnostics Receives Funding for Commercialisation of PoC Platform..... 174
 - QuantuMDx and Molbio announce MoU..... 176

Immunexpress Wins \$745K Contract for Rapid Sepsis Assay 178

Mobidiag Inks European, Middle Eastern Distribution Deals 179

BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial..... 179

bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels..... 180

XCR Diagnostics and Luminex Enter into License Agreement..... 181

Palmetto Final LCD Denies Coverage to Large Respiratory Panels..... 182

Karius Test to Be Available in Brazil..... 184

Inflammatix HostDx™ Fever Test able to Rapidly Distinguish Bacterial from Viral Infections 185

Panagene's STD kit gains Approval..... 186

GenePOC's Investment Validated by Medicare Decision..... 187

Startup Prominex Raises \$4M in Series A1 189

Alveo Closes Financing to Create Accessible Diagnostics Devices..... 189

MBio Diagnostics, Inc. Funding Supports Scaling of PoC Testing Platform..... 190

GenePOC® launches its GenePOC® CDiff test in Canada..... 191

Siemens Healthineers completes takeover of Fast Track Diagnostics 192

Chembio and FIND to Develop Point-of-Care Multiplex Test 192

Applied BioCode Receives CE Mark for 18-plex Gastrointestinal Pathogen Panel..... 194

Rapid Molecular Flu Tests Gain Ground..... 195

Cepheid Receives FDA Clearance and CLIA Waiver for Xpert® Xpress Flu Test 197

bioMérieux seeksr FDA Clearance of Pneumonia Panel..... 198

Mobidiag Announces Release of a Multiplex qPCR Test for Detection of Antibiotic Resistant Bacteria 200

Fast Track Diagnostics Gets CE Mark for Real-Time PCR Detection of High-Risk HPV 201

SEEGENE develops Multiplex PCR tests in 4 days 201

Seegene enters the U.S. diagnostic market in collaboration with Thermo Fisher Scientific . 203

Fusion Genomics Developing All Pathogens Diagnostic..... 204

Anapa Biotech Announces MeltPlex® Technology 205

First multiplex test for tick-borne diseases 206

ArcherDx, MGH Suing Qiagen Over Anchored Multiplex PCR Technology 207

Akoni Biosystems Forms Chinese Commercialization Partnership with Righton 208

Vela Buys Great Basin Scientific 209

BARDA Awards up to \$30M to Cue Health for Influenza, Respiratory Pathogen Test 210

QIAGEN enters into agreement to acquire STAT-Dx 210

GA-EMS receives diagnostic device contract..... 213

Biocartis & Immunexpress Sign Partnership for Sepsis..... 213

6. Profiles of Key Syndromic Testing Companies 215

 Abbott Diagnostics (Alere) 216

 Accelerate Diagnostics..... 218

 Ador Diagnostics 219

 Akoni Biosystems 220

 Alveo Technologies..... 221

 Applied BioCode..... 222

 Atlas Genetics..... 224

 Aus Diagnostics..... 225

 BD Diagnostics 227

 Biocartis..... 229

 BioFire Diagnostics..... 230

 bioMérieux..... 232

 Bio-Rad Laboratories..... 233

 Bosch Healthcare Solutions GmbH..... 235

 Cepheid..... 236

 Curetis 238

Diagenode Diagnostics..... 239

Diasorin 240

Fusion Genomics. 241

GenePOC Diagnostics 243

GenMark Dx 244

Hologic..... 245

Inflammatix..... 247

Invetech..... 248

Janssen Diagnostics 249

Karius 250

Lexigene 251

Luminex..... 252

Mbio Diagnostics 254

Mesa Biotech 255

Mobidiag 256

Nanomix..... 257

Oxford Nanopore 258

Panagene 259

Primerdesign..... 260

Prominex 261

Qiagen (Statdx) 262

Quantumdx..... 264

Roche Molecular Diagnostics..... 265

Seegene 267

Sensovation..... 268

Siemens Healthineers (Fast Track Diagnostics)..... 269

SkylineDx 275

T2 Biosystems 276

Thermo Fisher..... 277

Veramarx..... 279

XCR Diagnostics..... 280

7. Global Market Size..... 281

 7.1 Syndromic Global Market Size by Country with Charts 282

 7.2 Syndromic Global Market Size by Syndrome with Charts 284

8. Global Market by Syndrome..... 286

 8.1 Respiratory Syndrome Market 287

 8.1.1 Respiratory Syndrome Market by Country 287

 8.2 GI-Enteric Syndrome Market..... 289

 8.2.1 GI-Enteric Market by Country with Chart 289

 8.3 Blood-Sepsis Syndrome Market 291

 8.3.1 Blood-Sepsis Market by Country with Chart..... 291

 8.4 Meningitis Syndrome Market 293

 8.4.1 Meningitis Market by Country with Chart..... 293

 8.5 Sexually Transmitted Disease Syndrome Market..... 295

 8.5.1 Sexually Transmitted Disease Market by Country with Chart 295

 8.6 Other Syndrome Market..... 297

 8.6.1 Other Market by Country with Chart 297

9. Panel Testing Market – Volumes and Price Forecast with MDx Share 299

 9.1 Respiratory Panel Market 300

 9.2 GI-Enteric Panel Market 302

 9.3 Blood-Sepsis Panel Market 304

 9.4 Meningitis Panel Market 306

9.5 Sexually Transmitted Disease Panel Market..... 308

9.6 Other Panel Market..... 310

Appendices..... 312

I. United States Medicare System: 2018 Clinical Laboratory Fees Schedule – National Limit and Midpoint 312

II. FDA Approved Microbial Tests..... 364

Table of Tables

Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 (\$Billion) 35

Table 2 Classification of HIV Species..... 38

Table 3 HBV Tests - CMS Codes & Prices..... 68

Table 4 HCV Tests - CMS Codes & Prices..... 75

Table 5 HPV Clearance Rates..... 82

Table 6 HPV Tests - CMS Codes & Prices 87

Table 7 HPV Tests, Technology, Types..... 88

Table 8 Types of Influenza Tests..... 98

Table 9 Influenza Tests - CMS Codes & Prices..... 101

Table 10 FDA Cleared Molecular Assays for Influenza 103

Table 11 FDA Cleared NAAT CTGC Tests..... 115

Table 12 CTGC NAAT Target Sequences and Possible False Reactions 120

Table 13 Influenza Tests - CMS Codes & Prices..... 124

Table 14 FDA Approved MDx Tests for Tuberculosis..... 131

Table 15 Tuberculosis Tests - CMS Codes & Prices..... 132

Table 16 FDA Approved Tests for MRSA..... 135

Table 17 MRSA Tests - CMS Codes & Prices..... 137

Table 18 FDA Approved Tests for VRE 138

Table 19 VRE Tests - CMS Codes & Prices 139

Table 20 Market Players by Type 141

Table 21 Clinical Laboratory Departments and Segments..... 146

Table 22 Laboratory Management Focus – Different Approaches 147

Table 23 Key Segmentation Variables Going Forward 149

Table 24 Possible Market Segments of Syndromic Multiplex Market 149

Table 25 Five Factors Driving Growth..... 156

Table 26 How SMT Improves Outcomes 159

Table 27 Four Factors Limiting Growth 160

Table 28 Syndromic Global Market by Country/Region 282

Table 29 Syndromic Global Market by Syndrome 284

Table 30 Gi-enteric Syndromic Testing market by country 289

Table 31 Blood-sepsis Syndromic Testing market by country 291

Table 32 Meningitis Syndromic Testing market by country 293

Table 33 Sexually Transmitted Disease Syndromic Testing market by country 295

Table 34 Other Syndromic Testing market by country 297

Table 35 Respiratory Panel Testing market – North America 300

Table 36 Respiratory Panel Testing market – Europe 300

Table 37 Respiratory Panel Testing market – Asia Pacific 301

Table 38 GI-Enteric Panel Testing market – North America 302

Table 39 GI-Enteric Panel Testing market – Europe 302

Table 40 GI-Enteric Panel Testing market – Asia Pacific..... 303

Table 41 Blood-Sepsis Panel Testing market – North America..... 304

Table 42 Blood-Sepsis Panel Testing market – Europe 304

Table 43 Blood-Sepsis Panel Testing market – Asia Pacific 305

Table 44 Meningitis Panel Testing market – North America..... 306

Table 45 Meningitis Panel Testing market – Europe 306

Table 46 Meningitis Panel Testing market – Asia Pacific 307

Table 47 Sexually Transmitted Disease Panel Testing market – North America 308

Table 48 Sexually Transmitted Disease Panel Testing market – Europe..... 308

Table 49 Sexually Transmitted Disease Panel Testing market – Asia Pacific 309

Table 50 Other Panel Testing market – North America 310

Table 51 Other Panel Testing market – Europe..... 310

Table 52 Other Panel Testing market – Asia Pacific 311

Table 53 2018 Clinical Lab Fee Schedule..... 312

Table of Figures

Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 (\$Million)..... 34

Figure 2 HIV Virion 39

Figure 3 Diagram of the HIV Replication Cycle 43

Figure 4 The Structure of the HBV Virus 62

Figure 5 Hepatitis B Replication 63

Figure 6 Structure of the HCV Virus..... 70

Figure 7 HCV Replication Cycle 73

Figure 8 Structure of the Influenza Virion 95

Figure 9 Influenza Replication 96

Figure 10 Scanning Electronmicrograph of Tuberculosis 127

Figure 11 Chart Death Rates and Infectious Disease Decline 162

Figure 12 Comparing Syndromic and Targeted Testing 166

Figure 13 The Multiplex Paradigm Shift 167

Figure 14 Market Size by Country - Key Countries..... 283

Figure 15 Global Market by Country..... 283

Figure 16 Chart of Global Market by Syndrome 284

Figure 17 Growth Rates of Syndrome Segments 285

Figure 18 Chart - Respiratory market by country 288

Figure 19 Chart – Gi-enteric market by country..... 290

Figure 20 Chart – Blood-sepsis market by country 292

Figure 21 Chart - Meningitis market by country 294

Figure 22 Chart – Sexually Transmitted Disease market by country 296

Figure 23 Chart – Other Syndromic Testing market by country..... 298

1.1 What are Syndromic Multiplex Tests?

Syndromic Multiplex tests identify many infectious diseases with a single test.

Syndromic Multiplex Testing (SMT) are single tests that report back on the presence, or not, of several infectious diseases at the same time. Today the pattern is for a doctor, when faced with a patient who has some kind of cold/flu for instance, (a respiratory syndrome) to make a preliminary diagnosis and then to order a limited number, or just one, test to see if the diagnosis is correct. This is the traditional approach that goes back to the days when not all infectious diseases were known and they were recognized instead by their symptoms. The laboratory was used to confirm, or not, the diagnosis and often the disease was treated, and still is today, before the laboratory results were in. Tests were considered to be expensive and were ordered only as needed and often not at all.

These tests are DNA based and consequently are more accurate and specific.

The revolution in genetic knowledge has created technologies that can recognize multiple pathogens using a single test. This is called a multiplex test. The technology is DNA based so these tests tend to be very much more accurate than traditional testing methods. And because of this DNA base the possibility exists of identifying specific classes of pathogens, e.g. those resistant to certain antibiotics.

A syndrome is a group of symptoms that are often seen together and suggest the presence of one or more infectious diseases. The GI-Enteric Syndrome for instance, might often just be referred to by its main symptom, diarrhea. So diagnostic tests are being developed that test for a wide range of pathogens, in a single test, that might cause this symptom. This Syndromic Multiplex testing approach costs more initially, sometimes a lot more, but despite that is proving very popular.

Suppliers are providing different tests for different syndromes with different pathogens identified. These can be performed on smaller proprietary instruments and sometimes on traditional laboratory

positive. The three-gene-product approach to western blot interpretation has not been adopted for public health or clinical practice. Tests in which less than the required number of viral bands are detected are reported as indeterminate: a person who has an indeterminate result should be retested, as later tests may be more conclusive. Almost all HIV-infected persons with indeterminate western blot results will develop a positive result when tested in one month; persistently indeterminate results over a period of six months suggests the results are not due to HIV infection. In a generally healthy low-risk population, indeterminate results on western blot occur on the order of 1 in 5,000 patients. However, for those individuals that have had high-risk exposures to individuals where HIV-2 is most prevalent, Western Africa, an inconclusive western blot test may prove infection with HIV-2.

The HIV proteins used in western blotting can be produced by recombinant DNA in a technique called recombinant immunoblot assay (RIBA).

2.1.3.2 Point of Care Tests (POCT)

Rapid antibody tests are qualitative immunoassays intended for use in point-of-care testing to aid in the diagnosis of HIV infection. These tests should be used in conjunction with the clinical status, history, and risk factors of the person being tested. The positive predictive value of Rapid Antibody Tests in low-risk populations has not been evaluated. These tests should be used in appropriate multi-test algorithms designed for statistical validation of rapid HIV test results.

If no antibodies to HIV are detected, this does not mean the person has not been infected with HIV. It may take several months after HIV infection for the antibody response to reach detectable levels, during which time rapid testing for antibodies to HIV will not be indicative of true infection status. For most people, HIV antibodies reach a detectable level after two to six weeks. Although these tests have high specificity, false positives do occur. Any positive test result should be confirmed by a lab using the western blot.

Interpreting antibody tests

of anti-HBs is called the window period. A person negative for HBsAg but positive for anti-HBs either has cleared an infection or has been vaccinated previously.

Individuals who remain HBsAg positive for at least six months are considered to be hepatitis B carriers. Carriers of the virus may have chronic hepatitis B, which would be reflected by elevated serum alanine aminotransferase (ALT) levels and inflammation of the liver, if they are in the immune clearance phase of chronic infection. Carriers who have seroconverted to HBeAg negative status, in particular those who acquired the infection as adults, have very little viral multiplication and hence may be at little risk of long-term complications or of transmitting infection to others.

PCR tests have been developed to detect and measure the amount of HBV DNA, called the viral load, in clinical specimens. These tests are used to assess a person's infection status and to monitor treatment. Individuals with high viral loads, characteristically have ground glass hepatocytes on biopsy.

2.2.4 Market Opportunity Analysis

The market opportunity in HBV molecular diagnostics can be characterized broadly as

- Decreased window (zero) testing
- Point of care testing – nucleic acid based
- Genotyping

The traditional tests for HBV rely on detection of the antigen. These tests are limited by the time it takes for the full infection to develop and thereby produce the antigen in quantity. More sensitive nucleic acid based tests can reduce this “window” and have the opportunity to set a new detection standard.

Molecular Diagnostics (nucleic acid based testing) is moving into the Point of Care (eg. Emergency Ward) sphere. HBV with its relationship to drug use and sexual transmission is an important area for POC testing.

4.4.1 Comparing Syndrome and Targeted Testing

Syndromic testing, and its popularity, represent a shift in thinking about diagnosis. Traditionally diagnosis is done by a doctor with the lab tests confirming (or not) the diagnosis. In the syndromic testing paradigm, *the diagnosis shifts to the lab*. The doctor, recognizing the limits of their craft, lets the lab do the real work, and often saves physician time in the process. It is no wonder that time pressed Emergency Room physicians are enthusiastic adopters. Working against this is a very traditional view, control costs by stopping physicians from ordering unnecessary and expensive tests. This narrow view ignores the broader cost picture and the goal of the medical system, better care.




FIGURE 12 COMPARING SYNDROMIC AND TARGETED TESTING

Recent Developments – Importance and How to Use This Section

Importance of These Developments

Many users, especially those in the financial community, have noted that this section of the report can be extremely valuable in helping to understand industry current events and the evolution of key market players. These items are not chosen at random. They have been selected by the author(s) as significant and worth reading about, i.e. important. Please keep this in mind in reviewing them.

How to Use This Section

These items are NOT in date order. They are in the order in which they have been added to the report. This report is updated regularly, and new items are incorporated, and others removed. Numbering of items may not be sequential. Generally newer items are in the lower part of this section and have the highest numbers. Please refer to the date of an item to understand its currency. Reading this entire section is recommended for those not familiar with the industry. Many of the trends and issues noted elsewhere are illustrated in these actual events.

Akonni Biosystems Submits Multiplex Diagnostics System to FDA

Jan 04, 2019

Akonni Biosystems announced today it has submitted a molecular diagnostics system to the US Food and Drug Administration for 510(k) clearance. The system can perform multiplex testing using on-slide PCR and microarray technologies.

The system, called TruDiagnosis, consists of the TruDx imager, TruArray consumable test kit, and TruSpot software. The firm did not disclose whether a specific diagnostic assay was submitted along with the TruDiagnosis system.

The submission marks "a significant milestone" for the company, CEO and Founder Charles Daitch said in a statement, representing a critical next step in realizing Akonni's mission "to develop, manufacture, and sell molecular diagnostic tools for rapid, affordable, and

Aus Diagnostics

AusDiagnostics Pty. Ltd.
 290-292 Coward Street
 Mascot NSW 2020, Australia
 ABN 84 612 059 686

<http://www.ausdiagnostics.com>

TEL. +61 2 9698 8030

Revenue: ~\$7.5M

Description:

This privately held company was founded in 2006 by the current Managing Director. The company offers a wide range of syndromic multiplexing kits using a distributor strategy with offices in the UK and New Zealand. The company is active in a wide range of markets beyond human medical syndromic multiples testing, including veterinary and environmental assay markets.

The company offers a robust kit product line with several panel options in each of the following Syndrome categories

Respiratory	GI Enteric
Meningitis	Sepsis
Sexually Transmitted Disease	Bacterial Resistance
Parasites	HPV

The instrument lineup consists of:

A High-Plex System with two main parts: the Sample Processor and a Real-time PCR analyser. This can be supplemented by a nucleic acid extracton machine

Sample Processor. It performs sample handling, runs up to 24 (High-Plex) or up to 48 (Ultra-Plex) reactions and sets up 96-well or 384-well Real-